Compare Stocks: ALVO, ADPT, OGN, and LEGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADPT Adaptive Biotechnologies	$22.50 -0.3%	$19.43	$10.19 ▼ $24.57	$3.60B	2.08	2.32 million shs	541 shs
ALVO Alvotech	$4.01 -2.7%	$3.57	$2.94 ▼ $9.25	$1.21B	0.18	629,537 shs	4,599 shs
LEGN Legend Biotech	$18.74 +1.0%	$27.98	$16.24 ▼ $39.16	$3.48B	0.34	2.50 million shs	1,141 shs
OGN Organon & Co.	$13.55	$13.47	$5.69 ▼ $13.60	$3.56B	1.54	6.06 million shs	224 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADPT Adaptive Biotechnologies	0.00%	+1.35%	+6.51%	+58.16%	+118.49%
ALVO Alvotech	0.00%	+34.64%	+14.13%	+19.08%	-53.13%
LEGN Legend Biotech	0.00%	-16.52%	-37.98%	-21.36%	-52.19%
OGN Organon & Co.	0.00%	+0.22%	-0.07%	+1.96%	+38.88%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADPT Adaptive Biotechnologies	$22.50 -0.3%	$19.43	$10.19 ▼ $24.57	$3.60B	2.08	2.32 million shs	541 shs
ALVO Alvotech	$4.01 -2.7%	$3.57	$2.94 ▼ $9.25	$1.21B	0.18	629,537 shs	4,599 shs
LEGN Legend Biotech	$18.74 +1.0%	$27.98	$16.24 ▼ $39.16	$3.48B	0.34	2.50 million shs	1,141 shs
OGN Organon & Co.	$13.55	$13.47	$5.69 ▼ $13.60	$3.56B	1.54	6.06 million shs	224 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADPT Adaptive Biotechnologies	0.00%	+1.35%	+6.51%	+58.16%	+118.49%
ALVO Alvotech	0.00%	+34.64%	+14.13%	+19.08%	-53.13%
LEGN Legend Biotech	0.00%	-16.52%	-37.98%	-21.36%	-52.19%
OGN Organon & Co.	0.00%	+0.22%	-0.07%	+1.96%	+38.88%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADPT Adaptive Biotechnologies	2.57	Moderate Buy	$23.33	3.70% Upside
ALVO Alvotech	2.00	Hold	$7.60	89.53% Upside
LEGN Legend Biotech	2.53	Moderate Buy	$55.29	195.01% Upside
OGN Organon & Co.	1.71	Reduce	$11.40	-15.87% Downside

Current Analyst Ratings Breakdown

Latest ALVO, ADPT, OGN, and LEGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2026	LEGN Legend Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/30/2026	ADPT Adaptive Biotechnologies	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$22.00 ➝ $25.00
7/30/2026	ADPT Adaptive Biotechnologies	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$20.00 ➝ $22.00
7/30/2026	ADPT Adaptive Biotechnologies	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$25.00 ➝ $28.00
7/30/2026	ADPT Adaptive Biotechnologies	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$24.00 ➝ $25.00
7/28/2026	LEGN Legend Biotech	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/28/2026	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$65.00
7/27/2026	LEGN Legend Biotech	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$49.00 ➝ $28.00
7/27/2026	LEGN Legend Biotech	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$58.00
7/27/2026	LEGN Legend Biotech	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$63.00 ➝ $59.00
7/24/2026	LEGN Legend Biotech	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$49.00 ➝ $28.00

(Data available from 8/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADPT Adaptive Biotechnologies	$276.98M	13.00	N/A	N/A	$1.47 per share	15.31
ALVO Alvotech	$588.90M	2.06	$0.21 per share	18.91	($0.94) per share	-4.27
LEGN Legend Biotech	$1.14B	3.06	N/A	N/A	$5.43 per share	3.45
OGN Organon & Co.	$6.13B	0.58	$5.79 per share	2.34	$2.89 per share	4.69

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADPT Adaptive Biotechnologies	-$59.50M	-$0.41	N/A	N/A	N/A	-20.73%	-36.81%	-13.77%	N/A
ALVO Alvotech	$27.92M	-$0.25	N/A	12.53	N/A	-14.36%	-11.92%	-7.59%	8/19/2026 (Estimated)
LEGN Legend Biotech	-$296.80M	-$0.68	N/A	12.01	N/A	-21.98%	-24.92%	-14.87%	8/11/2026 (Estimated)
OGN Organon & Co.	$187M	$0.77	17.60	3.94	1.25	3.41%	92.94%	6.04%	N/A

Latest ALVO, ADPT, OGN, and LEGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/19/2026	Q2 2026	ALVO Alvotech	-$0.0526	N/A	N/A	N/A	$103.00 million	N/A
8/11/2026	Q2 2026	LEGN Legend Biotech	$0.0563	N/A	N/A	N/A	$355.96 million	N/A
7/28/2026	Q2 2026	ADPT Adaptive Biotechnologies	-$0.1336	-$0.25	-$0.1164	-$0.25	$65.44 million	$71.55 million
5/13/2026	Q1 2026	LEGN Legend Biotech	-$0.02	-$0.03	-$0.01	-$0.30	$306.51 million	$305.10 million
5/7/2026	Q1 2026	ALVO Alvotech	-$0.07	-$0.09	-$0.02	N/A	$112.39 million	$105.90 million
5/5/2026	Q1 2026	ADPT Adaptive Biotechnologies	-$0.16	-$0.13	+$0.03	-$0.13	$61.03 million	$70.87 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADPT Adaptive Biotechnologies	N/A	N/A	N/A	N/A	N/A
ALVO Alvotech	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.59%	N/A	10.39%	N/A

Latest ALVO, ADPT, OGN, and LEGN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/31/2026	OGN Organon & Co.	quarterly	$0.02	0.59%	8/14/2026	8/14/2026	9/10/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADPT Adaptive Biotechnologies	2.22	4.79	4.68
ALVO Alvotech	N/A	1.76	0.88
LEGN Legend Biotech	N/A	2.13	2.05
OGN Organon & Co.	9.47	1.97	1.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADPT Adaptive Biotechnologies	99.17%
ALVO Alvotech	N/A
LEGN Legend Biotech	70.89%
OGN Organon & Co.	77.43%

Insider Ownership

Company	Insider Ownership
ADPT Adaptive Biotechnologies	5.70%
ALVO Alvotech	N/A
LEGN Legend Biotech	0.02%
OGN Organon & Co.	1.62%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADPT Adaptive Biotechnologies	790	160.04 million	150.92 million	Optionable
ALVO Alvotech	1,460	301.81 million	N/A	Not Optionable
LEGN Legend Biotech	2,965	185.74 million	185.70 million	Optionable
OGN Organon & Co.	10,000	262.61 million	258.36 million	Not Optionable

ALVO, ADPT, OGN, and LEGN Headlines

Recent News About These Companies

Organon & Co. (NYSE:OGN) and Avantor (NYSE:AVTR) Head to Head Analysis

August 1 at 1:58 AM | americanbankingnews.com

Organon & Co. (NYSE:OGN) to Issue $0.02 Quarterly Dividend

July 31 at 6:49 PM | marketbeat.com

Organon & Co. (NYSE:OGN) Issues Earnings Results, Misses Expectations By $0.02 EPS

July 31 at 5:40 PM | marketbeat.com

Organon: Q2 Earnings Snapshot

July 31 at 2:43 PM | stamfordadvocate.comS

Compared to Estimates, Organon (OGN) Q2 Earnings: A Look at Key Metrics

July 31 at 12:01 PM | zacks.com

Organon (OGN) Lags Q2 Earnings Estimates

July 31 at 10:46 AM | zacks.com

Organon Announces Quarterly Dividend

July 31 at 9:00 AM | businesswire.com

Organon Reports Q2 Results Amid Pending Sun Pharma Merger

July 31 at 8:50 AM | tipranks.com

Orographic Financial Advisors LLC Acquires New Holdings in Organon & Co. $OGN

July 31 at 6:07 AM | marketbeat.com

Organon & Co. (NYSE:OGN) Receives Average Rating of "Reduce" from Brokerages

July 30, 2026 | marketbeat.com

First Trust Advisors LP Has $19.33 Million Position in Organon & Co. $OGN

July 30, 2026 | marketbeat.com

Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know

July 28, 2026 | zacks.com

Organon & Co. (OGN) to Announce Quarterly Earnings on Tuesday

July 28, 2026 | marketbeat.com

These mid-cap stocks combine A-rated profitability with attractive forward valuations

July 27, 2026 | msn.com

Orogen Royalties Announces Project, Partner and Royalty Update

July 27, 2026 | accessnewswire.comA

New Analysis of Phase 3 Pooled Data for Organon's VTAMA® (tapinarof) cream, 1%, Demonstrates Early, Consistent Improvements in Atopic Dermatitis Patients Across Pediatric Age Groups and in Adults1

July 24, 2026 | businesswire.com

Sun Pharma Clears Key Hurdle as Organon Shareholders Approve Acquisition

July 23, 2026 | tipranks.com

Organon & Co. Shareholders Clear Sun Pharma Merger Deal

July 23, 2026 | marketbeat.com

Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing

July 16, 2026 | businesswire.com

Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It

July 15, 2026 | zacks.com

Organon & Co.

July 15, 2026 | marketwatch.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ALVO, ADPT, OGN, and LEGN Company Descriptions

Adaptive Biotechnologies NASDAQ:ADPT

$22.50 -0.07 (-0.31%)

As of 08:58 AM Eastern

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Alvotech NASDAQ:ALVO

$4.01 -0.11 (-2.67%)

As of 08:42 AM Eastern

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Legend Biotech NASDAQ:LEGN

$18.74 +0.19 (+1.02%)

As of 08:32 AM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Organon & Co. NYSE:OGN

$13.55 0.00 (0.00%)

As of 08:05 AM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALVO, ADPT, OGN, and LEGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALVO, ADPT, OGN, and LEGN Earnings

Compare Dividends

Latest ALVO, ADPT, OGN, and LEGN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALVO, ADPT, OGN, and LEGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ALVO, ADPT, OGN, and LEGN Company Descriptions

Adaptive Biotechnologies NASDAQ:ADPT

Alvotech NASDAQ:ALVO

Legend Biotech NASDAQ:LEGN

Organon & Co. NYSE:OGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools